MedTrace Logo

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

NCT06047860 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-09-21

No results posted yet for this study

Summary

Exploring the efficacy and safety of recombinant human vascular endothelial inhibitor (Endo) in combination with Bragg therapy in advanced refractory non-small cell lung

Conditions

  • Advanced Solid Tumor
  • Refractory Tumor

Interventions

RADIATION

Radiotherapy

hypofractionated radiotherapy/SBRT

DRUG

PD-1/PD-L1 inhibitor

PD-1/PD-L1 inhibitor within one week of radiotherapy

DRUG

Granulocyte-macrophage colony-stimulating factor subcutaneous injection

IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;

DRUG

Interleukin 2 subcutaneous injection

IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;

DRUG

Endostatin

Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2024-12-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06047860 on ClinicalTrials.gov